Today’s stock market focus is centered on one single sector: technology stocks. The excitement around artificial intelligence ...

Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Shares of Pfizer Inc. PFE rallied 3.63% to $25.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

Researchers at NYU Tandon School of Engineering have developed a new method for creating microscopic drug delivery capsules ...

Here are nine new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...